Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $1 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23.9% | -15.3% | -69.3% | -124% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.9% | 53.7% | 20.4% | – |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |